Pediatrix Medical Group, Inc. (NYSE:MD) Shares Purchased by Barclays PLC

Barclays PLC boosted its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 302.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 142,087 shares of the company’s stock after purchasing an additional 106,817 shares during the period. Barclays PLC owned about 0.17% of Pediatrix Medical Group worth $1,646,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the second quarter valued at $31,000. Innealta Capital LLC acquired a new position in Pediatrix Medical Group in the 2nd quarter valued at about $33,000. Quest Partners LLC increased its stake in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after purchasing an additional 622 shares during the period. Quarry LP lifted its position in shares of Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after purchasing an additional 1,662 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at approximately $72,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft upped their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Jefferies Financial Group boosted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Macquarie assumed coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They issued an “outperform” rating and a $18.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $16.42.

Pediatrix Medical Group Trading Down 1.2 %

NYSE MD opened at $13.49 on Friday. The firm’s fifty day moving average price is $14.29 and its 200 day moving average price is $11.15. Pediatrix Medical Group, Inc. has a 12 month low of $6.62 and a 12 month high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -4.41, a price-to-earnings-growth ratio of 2.00 and a beta of 1.57.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.29 earnings per share. On average, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.